The University of California, Davis (UC Davis) is requesting continued support for the Clinical and Translational Science Center (CTSC). Since its initiation, the UC Davis CTSC has been firmly established as a major local, regional, and national leader in transforming the clinical and translational research enterprise and has received enthusiastic support from throughout UC Davis. The CTSC has created an extensive community of partners, ranging from the UC Davis Health System, colleges and schools to local community partners, regional partners including the University of Nevada and national partners, and other CTSA sites. The CTSC has fostered a cadre of successful trainees that are well prepared for a career trajectory in clinical and translational research, built an extensive infrastructure to support trainees, investigators, and community partners, and emerged as a major contributor to national CTSA goals. At the end of the initial funding period, the UC Davis CTSC is an organization that is: (1) responsive and familiar to investigators;(2) flexible;(3) versatile;(4) well-linked to university leadership, to participating academic units, and to the community;and (5) actively reducing barriers and facilitating translation of research gains into medical practice. The key features of our program are: education programs focused on """"""""team science"""""""";flexible infrastructure;extensive collaborations across UC Davis;and engagement of local, regional, and national partners. The CTSC has played major leadership roles in establishing the national CTSA Consortium, and has been a leader or collaborator on 15 CTSA supplemental awards. In the next grant period, the CTSC will focus on 3 goals firmly anchored in our institutional fabric, the community, and the CTSA Consortium: (1) Completion of a comprehensive service and resource toolset for the research community;(2) Education and training of a well prepared workforce of trainees, staff, and investigators;and (3) Ensuring translational research is advanced to improve human health across the lifespan. To realize these goals, the CTSC will remain under the continued leadership of Lars Berglund, MD, PhD, supported by a cadre of directors and associate directors overseeing individual CTSC programs, and guided by a comprehensive committee structure designed to firmly anchor the CTSC with institutional leadership, faculty, trainees, the community, and the national CTSA Consortium.

Public Health Relevance

The UC Davis CTSC has established a strong training and infrastructure resource to support and promote health research. Through the CTSC, research findings relevant to health and disease are made available to health professionals and community members. In addition, the UC Davis CTSC is part of a national network to ensure a broad-based information exchange between scientists, health professionals, and community members.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Mentored Career Development Award (KL2)
Project #
2KL2RR024144-06
Application #
8233582
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Sawczuk, Andrea
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
6
Fiscal Year
2011
Total Cost
$769,500
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Mayadev, Jyoti; Lim, Jihoon; Durbin-Johnson, Blythe et al. (2018) Smoking Decreases Survival in Locally Advanced Cervical Cancer Treated With Radiation. Am J Clin Oncol 41:295-301
Bratt, Jennifer M; Chang, Kevin Y; Rabowsky, Michelle et al. (2018) Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation. J Immunol 200:3840-3856
Oskarsson, Björn; Rocke, David M; Dengel, Karsten et al. (2016) Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology 86:1159-63
Olszewski, Anna; Yanes, Amber; Stafford, Jessica et al. (2016) Development and Implementation of an Innovative Burn Nursing Handbook for Quality Improvement. J Burn Care Res 37:20-4
Godwin, Zachary; Lima, Kelly; Greenhalgh, David et al. (2016) A Retrospective Analysis of Clinical Laboratory Interferences Caused by Frequently Administered Medications in Burn Patients. J Burn Care Res 37:e10-7
Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40
Oskarsson, Björn; Horton, D Kevin; Mitsumoto, Hiroshi (2015) Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Neurol Clin 33:877-88
Erdembileg, Anuurad; Mirsoian, Annie; Enkhmaa, Byambaa et al. (2015) Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden. PLoS One 10:e0121947
Henry, Stephen G; Czarnecki, Danielle; Kahn, Valerie C et al. (2015) Patient-physician communication about early stage prostate cancer: analysis of overall visit structure. Health Expect 18:1757-68
Palmieri, Tina L; Taylor, Sandra; Lawless, MaryBeth et al. (2015) Burn center volume makes a difference for burned children. Pediatr Crit Care Med 16:319-24

Showing the most recent 10 out of 41 publications